KMT2A and leukemia: Based on these promising results in this difficult‐to‐treat patient cohort, Revumenib received breakthrough designation from the FDA and was approved for the treatment of relapsed or refractory leukemia with KMT2A‐rearrangements by the FDA in November 2024.